Skip to main content

Advertisement

SpringerLink
Log in

Perception of risk: The state of COX-2 selective inhibitors

  • Invited Commentary
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bombardier C, Laine L, Reicin A, et al.: VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520–1528.

    Article  PubMed  CAS  Google Scholar 

  2. Strand V, Hochberg MC: The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002, 47:349–355.

    Article  PubMed  CAS  Google Scholar 

  3. When Is a Medical Product Too Risky? An interview with FDA’s Top Drug Official. Available at: http://www.fda.gov/ fdac/features/1999/599 _med.html. Accessed March 4, 2005.

  4. Lazzaroni M, Bianchi Porro G: Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther 2004, 20(Suppl 2):48–58.

    Article  PubMed  CAS  Google Scholar 

  5. Slovic P: The risk game. Reliability, Engineering, and System Safety 1998, 59:73–77.

    Article  Google Scholar 

  6. Slovic P, Kraus N, Lappe H, Major M: Risk perception of prescription drugs: report on a survey in Canada. Can J Public Health 1991, 82:515–520; 538–544.

    Google Scholar 

  7. Slovic P: Perception of Risk. Science 1987, 236:280–285.

    Article  PubMed  CAS  Google Scholar 

  8. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247–1255.

    Article  PubMed  CAS  Google Scholar 

  9. Boers M, Dijkmans B, Gabriel S, et al.: Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 2004, 50:1734–1739.

    Article  PubMed  Google Scholar 

  10. White WB, Faich G, Whelton A, et al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002, 89:425–430.

    Article  PubMed  CAS  Google Scholar 

  11. Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104:2280–2288.

    Article  PubMed  CAS  Google Scholar 

  12. White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003, 92:411–418.

    Article  PubMed  CAS  Google Scholar 

  13. Rahme E, Pilote L, LeLorier J: Association between naproxen use and protection against acute myocardial infarction (erratum in Arch Intern Med 2002; 162:1858). Arch Intern Med 2002, 162:1111–1115.

    Article  PubMed  CAS  Google Scholar 

  14. Solomon DH, Glynn RJ, Levin R, Avorn J: Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099–1104.

    Article  PubMed  CAS  Google Scholar 

  15. Ray WA, Stein CM, Hall K, et al.: Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359:118–123.

    Article  PubMed  CAS  Google Scholar 

  16. Solomon DH, Schneeweiss S, Glynn RJ, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068–2073.

    Article  PubMed  CAS  Google Scholar 

  17. Graham DJ, Campen D, Cheetham C, et al.: Risk of acute myocardial infarction and sudden cardiac death associated with use of COX-2 selective and nonselective NSAIDs [abstract]. Paper Presented at the 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Bordeaux, France, August 22–25, 2004.

  18. Whelton A, Fort JG, Pumpa JA, et al.: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients (erratum in Am J Ther 2001; 8:220). Am J Ther 2001, 8:85–95.

    Article  PubMed  CAS  Google Scholar 

  19. Whelton A, White WB, Bello AE, et al.: Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002, 90:959–963.

    Article  PubMed  CAS  Google Scholar 

  20. Sowers JR, White WB, Pitt B, et al.: For the Celecoxib Rofecoxib Efficacy and Safety in Co-morbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors andnonsteroidal antiinflammatory therapy on 24-hour blood pressure in hypertensive patients with osteoarthritis and type 2 diabetes mellitus. Arch Intern Med 2005, 165:551.

    Article  Google Scholar 

  21. White WB, Strand V, Roberts R, Whelton A: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004, 11:244–250.

    Article  PubMed  Google Scholar 

  22. Ott E, Nussmeier NA, Duke PC, et al.: For the Multicenter Study of Perioperative Ischemia (McSPI) Research Group and the Ischemia Research and Education Foundation (IREF) Investigators. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003, 125:1481–1492.

    Article  PubMed  CAS  Google Scholar 

  23. Farkouh ME, Kirshner H, Harrington RA, et al.: TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364:675–684.

    Article  PubMed  CAS  Google Scholar 

  24. Walter MF, Jacob RF, Day CA, et al.: Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004, 177:235–243.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 5A, 02115, Boston, MA, USA

    Lee S. Simon MD

Authors
  1. Lee S. Simon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vibeke Strand MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simon, L.S., Strand, V. Perception of risk: The state of COX-2 selective inhibitors. Curr Rheumatol Rep 7, 163–166 (2005). https://doi.org/10.1007/s11926-996-0032-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-996-0032-4

Keywords

Search

Navigation